SCHEMBL6318002

SCHEMBL6318002

CCCCNC(=O)c1c(-c2cccnc2)noc1N

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.50
ALDH1A1 P00352 2/20 0.48
HDAC1 Q13547 3/20 0.46
HDAC3 O15379 3/20 0.46
HDAC2 Q92769 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
PKM P14618 1/20 0.45
HIF1A Q16665 1/20 0.44
HDAC6 Q9UBN7 4/20 0.43
NCOR2 Q9Y618 2/20 0.43
HDAC4 P56524 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
KDM4E B2RXH2 1/20 0.43
PLAU P00749 2/20 0.43
POLB P06746 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316924 0.97 GAA (0.49) GAAALDH1A1HDAC1HDAC3HDAC2
SCHEMBL6315661 0.96 GAA (0.48) GAAALDH1A1HDAC1HDAC3HDAC2
SCHEMBL6321937 0.96 GAA (0.48) GAAALDH1A1HDAC1HDAC3HDAC2
SCHEMBL6322760 0.96 GAA (0.48) GAAALDH1A1HDAC1HDAC3HDAC2
SCHEMBL6318157 0.92 TP53 (0.47) GAAALDH1A1HDAC1HDAC3HDAC2
SCHEMBL6323477 0.88 ALDH1A1 (0.46) GAAALDH1A1HDAC1HDAC3HDAC2
SCHEMBL6323619 0.86 L3MBTL1 (0.62) ALDH1A1HDAC1HDAC3HDAC2L3MBTL1
SCHEMBL6315451 0.86 ALDH1A1 (0.47) GAAALDH1A1HDAC3L3MBTL1HDAC6
SCHEMBL6317724 0.85 L3MBTL1 (0.58) ALDH1A1HDAC1HDAC3HDAC2L3MBTL1
SCHEMBL6317397 0.85 TSHR (0.43) GAAALDH1A1HDAC1HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 GAA 789/4885ALDH1A1 4444/4885HDAC1 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.